



IPO NOTE

NEPHROCARE HEALTH SERVICES



Rating:

SUBSCRIBE



ISSUE OFFER

Issue Opens on	DEC 10, 2025
Issue Close on	DEC 12, 2025
Total IPO size (cr)	₹871.05 CR
Fresh issue (cr)	₹353.40 CR
Offer For Sale (cr)	₹517.64 CR
Price Band (INR)	₹ 438-460
Market Lot	32 SHARES
Face Value (INR)	₹2
Listing At	BSE, NSE
Market Capitalization (cr)	₹ 4,615 CR

ISSUE BREAK-UP (%)

QIB Portion	<div><div></div></div>	50%
NII Portion	<div><div></div></div>	15%
Retail Portion	<div><div></div></div>	35%

INDICATIVE TIMETABLE

Basis of Allotment	15-12-2025
Refunds/Unblocking ASBA Fund	16-12-2025
Credit of Share to Demat A/c	16-12-2025
Listing Date	17-12-2025

Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.


OBJECTS OF THE ISSUE

- Capital expenditure by the Company for opening new dialysis clinics in India
- Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
- General corporate purposes

FINANCIALS (RESTATED CONSOLIDATED)

PARTICULARS (IN CRORE)	FY 2025	FY 2024	FY 2023
Equity Share Capital	1.76	1.74	1.74
Net Worth	594.21	423.55	384.73
Total Income	769.92	574.72	443.26
EBITDA Margin%	21.6%	17.3%	11.0%
Net Profit/Loss of the year	67.10	35.13	-11.79

FINANCIAL RATIOS OF FY25



ROCE



P/E (Pre IPO)



EPS (Pre IPO)

OUTLOOK & VALUATION

- The company provides end-to-end dialysis care services across the globe.
- It stands as Asia's largest and the world's fifth-largest dialysis service provider.
- The company has delivered steady growth in both revenue and profits over the reported periods.
- However, increased finance costs have weighed down its bottom line in H1 FY26.
- Based on the latest financials, the issue seems aggressively valued.
- Only aggressive long-term investors should apply in this IPO.



COMPANY PROFILE

- The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy.
- As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world's largest dialysis clinic in Uzbekistan.
- In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions.
- Nephrocare has formed strategic partnerships with established hospital chains such as Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers.



COMPETITIVE STRATEGIES

- Continue to consolidate leadership position in India
- Scale operations in existing international markets including through inorganic growth opportunities
- Expand further in South East Asia, Commonwealth of Independent States and Middle East markets
- Continue to focus on operating efficiency and leveraging network scale to drive supply chain benefits and profitability
- Continue to focus on innovation led digital healthcare to enhance convenience, efficiency and reach



KEY CONCERNS

- Capital-intensive model requiring continuous funding support.
- Quality control challenges across a large clinic network.
- Dependent on kidney disease prevalence and policy support.
- Increasing competition from hospitals and local players.
- High operating costs may pressure profitability margins.



KEY STRENGTHS

- Asia's largest dialysis provider by treatment volumes.
- 447 centres ensuring broad national geographic reach.
- Innovative models like holiday and mobile dialysis.
- Strong patient base of over 33,000 annually.
- Experienced management backed by private equity funding.

COMPARISON WITH LISTED INDUSTRY PEERS

Name of the Company	EPS (₹ Basic)	P/E	NAV	Revenue (cr.)	RoNW%
Nephrocare Health Services Ltd.	8.28	63.52	59.56	755.8	13.19
Peer Group					
Narayana Health	38.90	45.21	160.35	5482.9	21.77
Jupiter Life Line Hospitals	29.47	51.10	192.55	1261.5	14.27
Rainbow Children Hospital	23.97	56.84	134.69	1515.8	16.56
Dr. Agarwal's Healthcare	2.80	179.42	55.13	1711.0	5.73
Dr. Lal Path Labs	58.48	52.47	245.26	2461.4	22.30
Metropolis Healthcare	28.29	69.48	236.34	1331.2	10.90
Vijaya Diagnostics	13.95	73.14	70.98	681.3	17.99



DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Ms. Sheetal Duraphe Email: compliance@swastika.co.in Phone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No. : NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532

CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.